Demographic Data |
Demographic Data |
Demographic Data |
Demographic
Data |
Age (years), mean ± SD |
66 ± 9 |
67 ± 10 |
0.243 |
Male gender, n (%) |
68 (76) |
80 (85) |
0.135 |
Heart failure condition |
Heart failure condition |
Heart failure
condition |
Heart failure condition |
Ischemic heart failure, n (%) |
49 (55) |
61 (65) |
0.101 |
LV ejection fraction (%), mean ± SD |
27 ± 6 |
28 ± 7 |
0.537 |
NHYA class I-II, n (%) |
70 (78) |
67 (71) |
0.250 |
Risk factors and history |
Risk factors and history |
Risk factors and
history |
Risk factors and history |
Hypertension, n (%) |
62 (70) |
64 (68) |
0.818 |
Diabetes mellitus, n (%) |
36 (40) |
42 (45) |
0.563 |
Smoking1, n (%) |
30 (34) |
34 (36) |
0.398 |
Dyslipidemia, n (%) |
55 (62) |
66 (70) |
0.669 |
Lung disease2, n (%) |
12 (14) |
10 (11) |
0.554 |
Obstructive Sleep Apnea, n (%) |
11 (12) |
12 (13) |
0.934 |
Stroke/transient ischemic attack, n (%) |
12 (14) |
20 (21) |
0.165 |
Atrial fibrillation (AF) |
34 (38) |
43 (46) |
0.302 |
Medication |
Medication |
Medication |
Medication |
ACEI/ARB/ARNI, n (%) |
85 (96) |
90 (96) |
0.937 |
Beta-blocker, n (%) |
81 (91) |
83 (88) |
0.548 |
Aldosterone antagosnists, n (%) |
49 (55) |
35 (37) |
0.016 |
Diuretic, n (%) |
66 (74) |
63 (67) |
0.290 |
Digoxin, n (%) |
8 (9) |
10 (11) |
0.708 |
Anti-arrhytmic drugs3, n (%) |
9 (10) |
15 (16) |
0.242 |
Oral anticoagulation, n (%) |
43 (48) |
49 (52) |
0.606 |
Type of device |
Type of device |
Type of device |
Type of
device |
Implantable cardioverter-defibrillator, n (%) |
47 (53) |
54 (57) |
0.528 |